© 2021 MJH Life Sciences and Urology Times. All rights reserved.
© 2021 MJH Life Sciences™ and Urology Times. All rights reserved.
June 17, 2021
Nearly two-thirds of patients with metastatic renal cell carcinoma responded to the combination.
June 16, 2021
“I think the data from this particular abstract pretty much reinforce that if you get avelumab as maintenance therapy, the time that patients spend in first- and second-line therapy is prolonged compared to patients who get best supportive care,” says Petros Grivas, MD, PhD.
June 15, 2021
Chung-Han Lee, MD, PhD, discusses the ongoing open-label phase 2 KEYNOTE-B61 study of frontline pembrolizumab plus lenvatinib in non-clear cell renal cell carcinoma.
June 14, 2021
Petros Grivas, MD, PhD, discusses posthoc findings from the phase 3 JAVELIN Bladder 100 trial presented during the 2021 ASCO Annual Meeting.
June 12, 2021
Toni K. Choueiri, MD, discusses the clinical and regulatory implications of the phase 3 KEYNOTE-564 trial, which explored pembrolizumab following nephrectomy in patients with clear cell renal cell carcinoma.
June 11, 2021
Benefits in progression-free survival and overall response rate were also observed for the pembrolizumab/lenvatinib arm across risk-defined subgroups.
June 10, 2021
The HIF-2α inhibitor continued to induce strong responses in patients with Von-Hippel Lindau (VHL)–associated renal cell carcinoma and other VHL-associated neoplasms.
June 09, 2021
A phase 2 study explored the addition of berzosertib to standard cisplatin/gemcitabine in patients with advanced urothelial cancer.
Data presented during the 2021 ASCO Annual meeting showed that fewer patients in the lenvatinib/everolimus arm were treated with subsequent anticancer treatments compared with patients in the sunitinib arm.
“Recurrence of urothelial cancer, in particular metastatic recurrence, is associated with a detriment in quality of life in this exploratory analysis,” says Matthew Galsky, MD.